AbCellera Biologics Income Statement 2025-2011 | ABCL

Brief overview of financial performance at AbCellera Biologics

The comparison covers a five-year financial horizon. According to figures from AbCellera Biologics, revenue changed from $233 million to $75.1 million over five years. The cumulative result was −67.8%, corresponding to roughly −20.3% per year. The business finished the period with a smaller revenue base.

EBITDA was 158 million dollars at the beginning and −199 million dollars at the end of the period (−225.5%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 67.9% to −264.4%. A lower EBITDA share weakens the quality of the result.

Across the five years, the net result shifted from 119 million dollars to −146 million dollars. Profit turned into a loss, the most concerning signal in the results.

Market capitalization changed from $6 billion to $962 million (−84%). Market expectations deteriorated over the period.

Financial takeaway

The results contain several connected negative signals. The most visible risks are pressure on operating profitability, weak sales momentum and lower investor confidence. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.